The Incidence of Occult Hepatitis C Virus Infection in Hemodialysed Patients With Liver Enzymes Disturbances

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by Meir Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01054664
First received: January 21, 2010
Last updated: NA
Last verified: January 2010
History: No changes posted
  Purpose

To assess the incidence of occult hepatitis C virus in hemodialysed patients with mild impairment of liver enzymes


Condition
Hemodialysed Patients With Impaired Liver Enzymes

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Meir Medical Center:

Estimated Enrollment: 30
Study Start Date: February 2010
Groups/Cohorts
impaired liver enzymes
normal liver enzymes
hepatitis C antibodies positive

Detailed Description:

occult hepatitis C virus will be checked in monocytes of hemodialyzed patients with permanent mild impairment of liver enzymes This population has no evidence of hepatitis B or C according to standard laboratory tests (HVC antibodies,HCV PCR, hepatitis B antibodies) Hepatitis C virus RNA will be performed in peripheral blood mononuclear cells of hemodialysed patients

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

hemodialysis patients with impaired liver enzymes

Criteria

Inclusion Criteria:

  • Hemodialysed patients with impaired liver enzymes

Exclusion Criteria:

  • hepatitis B and C positive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01054664

Contacts
Contact: Eleonora Plotkin, MD 972 9 7472517 nora.plotkin@clalit.org.il

Locations
Israel
Plotkin Eleonora Not yet recruiting
Kfar Saba, Israel
Contact: Osnat Klein, MD    972 9 7472517    Klein.Osnat@clalit.org.il   
Sponsors and Collaborators
Meir Medical Center
  More Information

No publications provided

Responsible Party: Plotkin Eleonora, Clalit Health services
ClinicalTrials.gov Identifier: NCT01054664     History of Changes
Other Study ID Numbers: nephrop003
Study First Received: January 21, 2010
Last Updated: January 21, 2010
Health Authority: Israel: The Israel National Institute for Health Policy Research and Health Services Research

Keywords provided by Meir Medical Center:
liver enzymes
peripheral mononuclear blood cells
hemodialysis
hepatitis C
RNA

Additional relevant MeSH terms:
Hepatitis
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections

ClinicalTrials.gov processed this record on August 01, 2014